APLI:CC News and Press, Appili Therapeutics Inc. From 06/29/22

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the fiscal year ended Mar...

Vancouver, Kelowna, Delta, BC - May 27, 2022 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Gaming, Plant-Based and Mining. Today's stocks have been added to our lists of fr...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Appili Therapeutics Inc. (TSX: APLI) (the “Company” or “Appili”) announced the closing of its previously announced public offering (the “Offering&...

IIROC Trade Resumption - APLI Canada NewsWire TORONTO , May 18, 2022 /CNW/ - Trading resumes in: Company: Appili Therapeutics Inc. TSX Symbol: APLI All Issues: Yes Resumption (ET): 9:30 AM IIROC can make a decision to impose a temporar...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Appili Therapeutics Inc. (TSX: APLI) (the “Company” or “Appili”) is pleased to announce today that it has priced its previously announced overnight marke...

IIROC Trading Halt - APLI Canada NewsWire TORONTO , May 17, 2022 /CNW/ - The following issues have been halted by IIROC: Company: Appili Therapeutics Inc. TSX Symbol: APLI All Issues: Yes Reason: Pending News Halt Time (ET): 4:01...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Appili Therapeutics Inc. (TSX: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today ...

Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced that Stéphane Paquette, Vice President, Corporate Development, will present at...

Topical formulation of paromomycin ATI-1801 already shown to be safe and effective against the disfiguring disease in Phase 3 study ATI-1801 may be eligible for tropical disease priority review voucher if approved by FDA Appili Therapeutics Inc. (TSX: APLI; OTCQX: AP...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious di...